New hope for rare blistering disease: rituximab vs standard care
NCT ID NCT03295383
First seen Mar 06, 2026 · Last updated May 13, 2026 · Updated 10 times
Summary
This study tests whether rituximab works better than the current standard drug cyclophosphamide for people with severe mucous membrane pemphigoid, a rare autoimmune disease that causes painful blisters and scarring on mucous membranes. About 130 adults will receive either drug plus a placebo, and researchers will track how many achieve remission. The goal is to find a safer, more effective treatment to prevent serious complications like blindness or trouble breathing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE FORMS OF MUCOUS MEMBRANE PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
APHM La Timone
RECRUITINGMarseille, France
Contact
Contact
-
APHP Avicennes
RECRUITINGParis, France
Contact
Contact
-
APHP Bichat
RECRUITINGParis, France
Contact
Contact
-
APHP Cochin
RECRUITINGParis, France
Contact
Contact
-
APHP Henri Mondor
RECRUITINGParis, France
Contact
Contact
-
APHP Pitié Salpétrière
RECRUITINGParis, France
Contact
Contact
-
APHP Saint-Louis
RECRUITINGParis, France
Contact
Contact
-
Brest University Hospital
RECRUITINGBrest, France
Contact
Contact
-
CH Argenteuil
RECRUITINGArgenteuil, France
Contact
Contact
-
CH Le Mans
RECRUITINGLe Mans, France
Contact
Contact
-
CH Quimper
RECRUITINGQuimper, France
Contact
Contact
-
CHU Amiens
RECRUITINGAmiens, France
Contact
Contact
-
CHU Angers
RECRUITINGAngers, France
Contact
Contact
-
CHU Bordeaux
RECRUITINGBordeaux, France
Contact
Contact
-
CHU Caen
RECRUITINGCaen, France
Contact
Contact
-
CHU Clermont Ferrand
RECRUITINGClermont-Ferrand, France
Contact
Contact
-
CHU Dijon
RECRUITINGDijon, France
Contact
Contact
-
CHU Lille
RECRUITINGLille, France
Contact
Contact
-
CHU Montpellier
RECRUITINGMontpellier, France
Contact
Contact
-
CHU Nantes
RECRUITINGNantes, France
Contact
Contact
-
CHU Nice
RECRUITINGNice, France
Contact
Contact
-
CHU Rennes
RECRUITINGRennes, France
Contact
Contact
-
CHU Tours
RECRUITINGTours, France
Contact
Contact
-
CHU de Limoges
RECRUITINGLimoges, France
Contact
Contact
-
CHU de Reims
RECRUITINGReims, France
Contact
Contact
-
CHU saint-Etienne
RECRUITINGSaint-Etienne, France
Contact
Contact
-
HCL
RECRUITINGLyon, France
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.